Clinical Trial Update: Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating Tagraxofusp in combination with a low-intensity chemotherapy regimen for CD123-positive relapsed or refractory acute myelo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Low-intensity chemotherapy regimen
• Tagraxofusp (tagraxofusp)

Snippet

Sponsor: Stanford University | Conditions: Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia | Phase 1, Phase 2 | Status: RECRUITING